Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Anthera Pharmaceuticals Inc (NASDAQ:ANTH)

0.6129
Delayed Data
As of Jan 19
 -0.037 / -5.69%
Today’s Change
0.61
Today|||52-Week Range
4.90
-5.58%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$27.3M

Company Description

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic fibrosis. It develops phase 3 product candidates, which includes blisibimod and liprotamase. Anthera Pharmaceuticals was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.

Contact Information

Anthera Pharmaceuticals, Inc.
25801 Industrial Boulevard
Hayward California 94545
P:(510) 856-5600
Investor Relations:
151085656005621

Employees

Shareholders

Other institutional27.38%
Mutual fund holders18.11%
Individual stakeholders0.62%

Top Executives

John Craig ThompsonPresident, Chief Executive Officer & Director
May LiuCAO, Senior VP-Finance & Administration
Charles V. OlsonChief Technology Officer
William R. ShanahanChief Medical Officer
Klara A. Dickinson-EasonChief Regulatory Officer & Senior Vice President